Imagine losing your independence – not from aging, but from a treatable condition that often goes undetected. Normal pressure hydrocephalus (NPH) is a serious yet underdiagnosed neurological disorder that affects millions, often misidentified as Alzheimer’s or Parkinson’s disease.
X-Pressure is changing the game with XP One, a smart cerebrospinal fluid (CSF) infusion testing device designed to detect NPH earlier and more accurately.
NPH: Prevalent, Misdiagnosed, and Treatable
By 2050, 1.6 billion people will be over 65 years old and an estimated 5% will suffer from NPH. But up to 80% of cases currently go undiagnosed – that’s millions of people and their loved ones left to face a degenerative condition that could be reversed with proper treatment.
NPH is caused by abnormal CSF buildup in the brain due to poor circulation. Its telltale symptoms – gait disturbances and falls, urinary incontinence, and cognitive decline – are often dismissed as typical aging or misdiagnosed as other neurodegenerative diseases.
Why NPH Diagnosis Is So Difficult
The challenge lies in subtle symptoms and overlapping imaging findings. Though NPH causes ventriculomegaly, brain scans alone can’t reliably distinguish it from cerebral atrophy or other age-related changes. Compounding the issue, physical symptoms are often non-specific and frequently attributed to other neurodegenerative diseases.
Accurate diagnosis requires a deeper look into cerebral hydrodynamics. That’s where CSF infusion testing comes in.
By introducing fluid into the subarachnoid space and measuring the brain’s response, infusion testing reveals critical metrics like CSF outflow resistance and brain elastance – helping clinicians to clearly identify NPH.
Patients who are shunted based on CSF infusion testing results can see significant symptom improvement, often regaining independence for five years or more.
Meet XP One: Smart Infusion Testing by X-Pressure
XP One is X-Pressure’s smart device for bedside CSF infusion testing – a modern, user-friendly tool built for today’s clinicians. XP One makes NPH detection easier and more accurate by facilitating the 20 minute, outpatient procedure and:
- Delivering real-time CSF outflow resistance measurements
- Auto-calibrating for flushless operation with any lumbar puncture needle
- Using proprietary algorithms based on 25+ years of multi-center data to analyze key CSF parameters
With seamless tablet and smartphone integration, XP One ensures secure, real-time data is always at your fingertips – standardizing testing and streamlining workflows.
Who Can Use XP One?
XP One supports a wide range of specialists:
- Neurosurgeons & neurologists seeking precise NPH detection tools
- Geriatricians & primary care physicians managing aging patients
- ICU teams assessing CSF dynamics in brain injury cases
By removing barriers like inconsistent protocols and limited access, XP One empowers clinicians to detect NPH confidently and earlier – when treatment is most effective.
The Vision Behind X-Pressure
X-Pressure was founded with one goal: to improve outcomes for NPH patients. Backed by 25+ years of clinical data and partnerships with leading researchers, XP One is the culmination of a deep commitment to advancing neurological care. As CEO Pierre de Lamy says, “The XP One device represents the culmination of our efforts to ensure every NPH patient receives timely, effective care.”
Coming Soon: XP One Launch Timeline
X-Pressure plans to launch XP One in the U.S. and Europe by 2026, pending FDA and CE mark approval. This development roadmap reflects our commitment to quality, safety, and global accessibility.
